Ava Fertility Tracker

Our Findings

• The privacy policy is strong and GDPR-aligned, with explicit post-Dobbs commitments stating that user data will never be sold or transferred. The security infrastructure appears solid on paper. However, the gap between stated policy and what actually happened to user data during the FemTec collapse is significant and documented.

Strengths

• No known data breaches or FTC actions
• The privacy policy explicitly states that data will never be rented, sold, or transferred to third parties.
• Privacy policy updated February 2024, GDPR-compliant, explicitly states data will never be rented, sold, or transferred to third parties.
• Post-Dobbs statement is very direct and specific: data is described as "never transferable, never releasable to anyone"
• AWS enterprise-grade storage referenced; GDPR compliance cited as exceeding HIPAA requirements for sensitive health data
• Data minimization appears reasonable, the physiological data collected is genuinely necessary for core product functionality
• Users retain rights to deletion, and the policy names a data protection coordinator with contact information

Weaknesses

• During the FemTec Health collapse, users reported losing access to years of stored fertility and cycle data without warning or communication from the company
• No documented remediation or acknowledgment from Awesome Health Inc. of the data access failures that occurred during the transition
• The privacy policy makes strong promises, but the organizational track record shows those promises are contingent on business stability, which has already failed once
• Third-party service providers (newsletter vendor, analytics, AWS) are referenced but not named or described in detail
• Deletion process is referenced but not described step-by-step in the main policy
• No SOC 2 or ISO 27001 certifications publicly documented
• Cookies used for marketing purposes with limited opt-out clarity

What We Couldn't Find

• Any public statement from Awesome Health Inc. acknowledging the data access failures during the FemTec collapse or detailing what remediation was offered
• Documentation of how user data was handled, migrated, or preserved during the FemTec → Awesome Health transition
• SOC 2, ISO 27001, or equivalent third-party security certification
• Full list of third-party vendors with access to user data
• Step-by-step data deletion process

Our Findings

• Strong accuracy findings. FDA 510(k)-cleared for ovulation prediction, CE-marked under EU MDR, and backed by 30+ peer-reviewed publications. The clinical research is substantive, and the product's limitations are disclosed, though those disclosures are more visible in FAQs than on the main product pages.

Strengths

• FDA 510(k) clearance (February 2021), making this the first and only FDA-cleared fertility tracking wearable at time of clearance; regulatory status directly matches the claims being made
• CE mark under EU Medical Device Regulation (MDR)
• 30+ peer-reviewed publications and presentations at medical congresses
• 2019 JMIR study (n=237) demonstrated 90% accuracy detecting the 5-day fertile window
• 2021 JMIR study showed wrist skin temperature superior to basal body temperature for detecting ovulation
• Clinical trials conducted in collaboration with University Hospital of Zurich, Columbia University, and Northwestern University Feinberg School of Medicine
• Substantive research relationships, not marketing affiliations
• Clearly discloses product is not for use as contraception
• Clearly discloses product is not validated for PCOS or cycles outside 24–35 days

Weaknesses

• The key accuracy study most prominently cited involved researchers who were Ava employees, flagged by Medical News Today as a reason to interpret accuracy figures with caution
• Significant limitations in accuracy based on cycle length and conditions like PCOS
• Third-party reviews but are not prominently featured on the main product or ordering pages
• "Double your chances of pregnancy" framing on homepage technically references a study about timed intercourse, not Ava specifically, presented in a way that implies the device itself doubles chances
• No independent post-FDA accuracy audits identified
• User reviews show meaningful inaccuracy complaints, particularly from users with cycles near the 24- or 35-day boundary

What We Couldn't Find

• Independent post-FDA accuracy audit not conducted by Ava-affiliated researchers
• Accuracy data for users at the edges of the eligible cycle range (24 or 35 days)
• Published outcomes data under Awesome Health Inc. ownership

Our Findings

• The original founding team built a credible, mission-aligned company with genuine expertise in women's health. That team is gone. The company was acquired by FemTec Health, whose founder, Dr. Kimon Angelides, has a documented federal finding of intentional scientific fraud, allegedly failed to pay Ava's own staff, including its CEO, during his ownership, and ran FemTec into collapse within 18 months. Awesome Health Inc., the current owner, has no visible leadership, no public mission statement, and has made no public accounting of what happened to users or the product under its stewardship. The credibility of the original founders cannot be transferred to the current organizational structure.

Strengths

• Original founding team (Lea von Bidder, Pascal Koenig et al.) had genuine, relevant expertise in women's health and medtech
• Under original leadership, Ava had a specific and consistently communicated mission, advancing women's reproductive health through AI and clinical research
• Strong historical research partnerships and academic collaborations
• Product marketing under original leadership was evidence-based and avoided exploitative or fear-based framing

Weaknesses

• Dr. Kimon Angelides, who acquired Ava via FemTec Health in July 2022, has a federal finding of intentional scientific fraud: the HHS Office of Research Integrity found he falsified data in five NIH grant applications and five published papers while at Baylor College of Medicine, resulting in a 5-year federal debarment
• The federal appeals panel explicitly characterized his conduct as "not honest error... but rather intentional and conscious fraud"
• During his ownership, Ava's CEO Lea von Bidder and other senior leaders filed with Switzerland's debt enforcement office alleging unpaid wages; Angelides had also allegedly misrepresented FemTec's financial and operational status to investors and vendors
• FemTec Health burned through $38M, acquired five unrelated companies, and collapsed via assignment for the benefit of creditors within 18 months of acquiring Ava — with no warning or transition plan for users
• Awesome Health Inc., the current operator, has no identified leadership on the Ava website, no updated mission statement, and no visible advisory board
• No current clinical advisors or governing structure publicly documented
• The company's public-facing identity still reads as if the original Ava AG team is running it, which is materially misleading

What We Couldn't Find

• Identity of current leadership at Awesome Health Inc.
• Any current advisory board or clinical governance structure
• Any public statement from Awesome Health Inc. acknowledging the FemTec-era harms to users or staff
• Updated mission statement or organizational values under current ownership
• Any disclosure to users that the company changed hands twice in less than two years

Our Findings

• A premium-priced device that explicitly does not work for PCOS users, which is one of the leading causes of fertility challenges. There are no meaningful economic accessibility pathways, no visible community health partnerships, and the product's marketing presents a narrow, largely homogeneous image of its users.

Strengths

• App available in multiple languages (German, Spanish, French, Italian, Polish, Czech)
• FSA/HSA eligible, which provides some relief for users with qualifying accounts
• Employer reimbursement available through Carrot Fertility and similar benefits platforms
• 20% of each bracelet sale goes toward women's health research and development
• Product content (AvaWorld blog) covers a reasonably broad range of reproductive health topics
• Ava initiated a PCOS/irregular cycle clinical trial in 2017, indicating early awareness of the limitation — though no product expansion has resulted

Weaknesses

• Priced at $279–$359 with no free tier, sliding scale, low-income discount, or Medicaid pathway, effectively inaccessible to a large share of the population it nominally serves
• Employer reimbursement pathway primarily benefits already-privileged users with comprehensive benefits packages
• Device explicitly not validated for PCOS or cycles outside 24–35 days — excluding a condition that is both common and disproportionately prevalent among women of color
• No evidence of diverse user testing populations or design validation across racial, ethnic, or body-size diversity
• Marketing imagery skews heavily toward a narrow, white, thin, presumably cis-heterosexual aesthetic
• No identified partnerships with community health organizations, reproductive health equity initiatives, or programs serving underserved populations
• Accessibility features (screen reader compatibility, adjustable UI) not documented

What We Couldn't Find

• Any outcomes from the 2017 PCOS clinical trial or product development resulting from it
• Accessibility documentation (screen reader support, UI accommodations)
• Community health partnerships or equity-focused initiatives
• Evidence of diverse user testing or design validation across demographic groups
• Any pricing accommodation for low-income users